SciClone Pharmaceuticals has significantly broadened its commercial footprint in China by purchasing the Shanghai-based speciality pharmaceutical company NovaMed Pharmaceuticals for approximately US$62 M upfront in cash and shares. NovaMed shareholders could also receive up to an additional US$43 M in cash, contingent upon the achievement of revenue and earnings targets for the 2011 and 2012 fiscal years. With the acquisition, SciClone will gain access to NovaMed’s portfolio of 18 marketed products along with an established, 450-strong sales force in China.